introduct
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
coronaviru
human
metapneumoviru
rhinoviru
repres
common
caus
respiratori
viral
infect
immunocompromis
patient
also
infect
may
sever
immunocompromis
patient
gener
popul
earli
diagnosi
treatment
viral
infect
continu
paramount
import
immunocompromis
patient
viral
replic
invas
infect
evid
prognosi
grave
area
cover
purpos
review
provid
overview
main
antivir
agent
use
treatment
respiratori
viral
infect
immunocompromis
patient
review
new
agent
pipelin
expert
commentari
past
decad
import
diagnost
advanc
specif
use
rapid
molecular
test
help
close
gap
clinic
scenario
pathogen
identif
enhanc
earli
diagnosi
viral
infect
understand
role
prolong
shed
viral
load
advanc
novel
antivir
therapeut
high
resist
threshold
effect
immun
prevent
infect
immunocompromis
patient
need
articl
histori
spectrum
immunocompromis
host
expand
past
decad
owe
prolong
surviv
patient
variou
malign
advanc
solidorgan
hematopoiet
stem
cell
transplant
novel
immunosuppress
therapi
creat
divers
immun
deficit
gener
substrat
opportunist
infect
patient
defin
higher
suscept
infect
organ
lower
nativ
virul
immunolog
normal
host
influenza
parainfluenza
respiratori
syncyti
viru
coronaviru
human
metapneumoviru
rhinoviru
repres
common
caus
respiratori
viral
infect
immunocompromis
patient
infect
season
virus
caus
wide
rang
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
howev
advers
outcom
far
like
immunocompromis
patient
nonimmunocompromis
individu
includ
progress
pneumonia
respiratori
failur
increas
mortal
rate
fact
lrti
rate
mortal
rate
hematopoiet
stem
cell
transplant
hsct
recipi
patient
hematolog
malign
reportedli
rang
longterm
complic
associ
respiratori
viral
infect
airflow
obstruct
bronchiol
obliteran
develop
hsct
lung
transplant
recipi
figur
highlight
high
rate
progress
lrti
death
among
immunocompromis
patient
common
respiratori
viral
infect
manag
viral
infect
challeng
virus
intracellular
parasit
use
mani
host
pathway
replic
propag
therefor
antivir
agent
need
target
specif
viral
compon
avoid
potenti
damag
host
cell
figur
highlight
life
cycl
viral
replic
site
action
variou
antivir
agent
advanc
treatment
respiratori
infect
made
past
decad
tabl
highlight
current
avail
agent
treatment
respiratori
viral
infect
tabl
list
agent
current
pipelin
differ
virus
purpos
review
provid
overview
main
antivir
agent
use
manag
respiratori
infect
immunocompromis
patient
focus
clinic
relev
experi
well
provid
updat
current
investig
agent
pipelin
influenza
viru
among
common
human
respiratori
virus
belong
orthomyxovirida
famili
four
type
influenza
virus
b
c
human
influenza
b
virus
caus
season
epidem
diseas
almost
everi
winter
unit
state
influenza
type
c
infect
caus
mild
respiratori
ill
thought
caus
epidem
influenza
virus
primarili
affect
cattl
known
infect
human
influenza
virus
group
subtyp
base
antigen
characterist
protein
surfac
hemagglutinin
ha
neuraminidas
na
differ
ha
subtyp
na
subtyp
influenza
virus
broken
differ
subtyp
common
subtyp
influenza
viru
affect
human
influenza
b
virus
group
subtyp
broken
lineag
current
circul
influenza
b
virus
belong
lineag
byamagata
bvictoria
season
preval
influenza
infect
immunocompromis
patient
includ
solidorgan
transplant
hsct
recipi
close
parallel
communitywid
preval
peak
decemb
februari
influenza
b
activ
sometim
seen
april
may
howev
ill
potenti
sever
popul
healthi
host
without
treatment
report
mortal
rate
rang
immunocompromis
patient
relat
complic
includ
pneumonia
bacteri
fungal
superinfect
retrospect
studi
identifi
profound
lymphocytopenia
absolut
lymphocyt
count
cell
ml
age
greater
year
neutropenia
absolut
neutrophil
count
cellsml
potenti
risk
factor
associ
progress
urti
lrti
earli
antivir
therapi
within
first
h
present
associ
improv
prognosi
sever
studi
two
main
group
antivir
use
treat
influenza
inhibitor
amantadin
rimantadin
act
influenza
na
inhibitor
activ
influenza
b
oseltamivir
zanamivir
peramivir
inhibitor
inhibit
ion
channel
protein
influenza
viru
lead
defect
uncoat
assembl
viru
figur
influenza
viru
enter
host
cell
via
receptormedi
endocytosi
thereaft
local
endocytot
vacuol
proton
channel
transport
ion
need
acidif
influenza
viru
insid
vacuol
acidif
requir
dissoci
protein
ribonucleoprotein
complex
onset
viral
replic
recommend
dose
amantadin
mg
given
daili
mg
given
twice
daili
durat
therapi
gener
day
common
side
effect
agent
gastrointestin
nausea
vomit
effect
central
nervou
system
includ
anxieti
insomnia
impair
think
confus
lightheaded
hallucin
resist
influenza
infect
inhibitor
result
mutat
porelin
residu
ion
channel
keep
adamantin
rimantadin
enter
channel
accord
data
world
health
organ
collabor
center
surveil
epidemiolog
control
influenza
us
center
diseas
control
prevent
cdc
rate
inhibitor
resist
increas
season
howev
season
rate
high
report
influenza
viru
recent
cdc
data
demonstr
high
preval
inhibitor
resist
influenza
influenza
viru
isol
test
current
current
advisori
committe
immun
practic
acip
guidelin
treatment
influenza
infect
recommend
routin
use
amantadin
rimantadin
usa
therapi
chemoprophylaxi
current
circul
influenza
viru
strain
nai
block
activ
site
neuraminidas
result
uncleav
sialic
acid
residu
host
cell
surfac
viral
envelop
figur
uncleav
sialic
acid
bound
viral
ha
caus
viral
aggreg
host
cell
surfac
reduc
amount
viru
releas
nai
virustat
virucid
earli
administr
key
factor
develop
resist
viru
effect
treatment
inhibitor
neither
delay
await
result
diagnost
test
withheld
infect
patient
indic
therapi
present
h
onset
symptom
particularli
patient
need
hospit
particular
nai
zanamivir
oseltamivir
firstlin
agent
treatment
prophylaxi
influenza
oseltamivir
oral
nai
usual
prescrib
mg
oral
twice
daili
renal
adjust
recommend
durat
antivir
therapi
day
howev
longer
durat
day
may
consid
sever
ill
patient
influenza
viru
strain
substitut
lead
resist
zanamavir
nai
intraven
zanamivir
avail
compassion
use
program
singl
dose
mg
administ
intraven
influenza
na
substitut
lead
resist
zanamivir
peramivir
nai
longer
durat
day
highrisk
patient
antivir
therapi
like
provid
benefit
initi
within
first
h
infect
occur
treatment
initi
soon
possibl
expert
recommend
higher
dose
oral
administ
oseltamivir
eg
mg
twice
daili
adult
normal
renal
function
treatment
influenza
infect
immunocompromis
patient
hospit
sever
ill
howev
clear
evid
indic
doubl
dose
oseltamivir
effect
treatment
administ
normal
prescrib
dose
hospit
patient
without
sever
ill
random
trial
hospit
patient
sever
influenza
mortal
rate
similar
patient
receiv
oseltamivir
doubl
standard
dose
howev
patient
standard
dose
arm
infect
influenza
viru
without
substitut
baselin
acquir
substitut
treatment
although
infer
made
far
due
small
number
patient
use
higher
dose
prevent
resist
clinic
failur
sever
ill
patient
immunocompromis
patient
still
need
determin
futur
studi
addit
prospect
studi
adult
hospit
influenza
b
infect
treat
singl
doubl
dose
oseltamivir
twice
daili
demonstr
differ
group
viral
clearanc
fever
durat
oxygen
supplement
hospit
length
patient
receiv
antivir
medic
whose
infect
respond
treatment
may
infect
antiviralresist
influenza
virus
author
report
oseltamivir
resist
sometim
occur
within
week
treatment
initi
immunocompromis
patient
influenza
viral
infect
pandem
genotyp
phenotyp
antivir
suscept
test
current
avail
check
presenc
mutat
confer
resist
common
emerg
resist
oseltamivir
immunocompromis
patient
probabl
partli
owe
prolong
viral
shed
despit
use
antivir
therapi
use
infect
control
measur
vital
reduc
risk
oseltamivirresist
viru
transmiss
immunocompromis
patient
pool
incid
rate
oseltamivir
resist
season
influenza
infect
estim
systemat
review
howev
europ
season
rate
influenza
resist
higher
author
report
specif
substitut
season
influenza
viru
strain
histidinetotyrosin
substitut
neuraminidas
caus
resist
case
circul
influenza
influenza
still
suscept
oseltamivir
zanamivir
influenza
infect
test
influenza
season
suscept
oseltamivir
suscept
zanamivir
usual
mild
limit
first
day
treatment
nausea
vomit
common
report
toxic
effect
oseltamivir
occur
recipi
zanamivir
administ
via
inhal
dose
inhal
inhal
twice
day
chemoprophylaxi
dosag
zanamivir
mg
inhal
administ
day
random
trial
treatment
shorten
durat
influenza
symptom
day
use
intraven
iv
zanamivir
evalu
recent
phase
iii
clinic
trial
efficaci
safeti
mg
mg
intraven
zanamivir
twice
daili
compar
mg
oral
oseltamivir
twice
daili
treatment
hospit
patient
influenza
infect
preliminari
analysi
show
statist
differ
time
clinic
respons
primari
outcom
variabl
iv
zanamivir
mg
oseltamivir
iv
zanamivir
mg
mg
current
avail
compassion
use
manufactur
via
us
fda
emerg
investig
new
drug
applic
compassionateus
program
europ
zanamivir
current
therapi
choic
oseltamivirresist
influenza
infect
howev
literatur
contain
case
influenza
viru
zanamivir
resist
infect
influenza
strain
possess
na
substitut
oseltamivir
resist
aspart
acid
replac
glutam
acid
posit
glycin
replac
glutam
acid
posit
na
substitut
resist
zanamivir
main
advers
reaction
zanamivir
relat
bronchospasm
use
inhal
powder
treat
influenza
infect
recommend
patient
underli
airway
issu
ie
chronic
obstruct
pulmonari
diseas
asthma
also
contain
lactos
carrier
clog
ventil
tube
nebul
mechan
ventil
peramivir
activ
influenza
b
approv
fda
treat
uncompl
influenza
infect
adult
first
nai
approv
iv
use
administ
singl
iv
dose
mg
strong
prolong
affin
na
influenza
viru
peramivir
use
consid
patient
unabl
toler
oral
enter
drug
use
singl
dose
mg
peramivir
administ
intraven
allevi
influenza
symptom
averag
h
sooner
fever
approxim
h
sooner
patient
given
placebo
publish
report
studi
patient
high
risk
complic
includ
patient
diabet
chronic
respiratori
diseas
receiv
immunosuppress
therapi
given
peramivir
day
demonstr
shorter
durat
ill
patient
given
singl
dose
henc
longer
durat
treatment
immunocompromis
patient
suggest
also
openlabel
random
studi
highrisk
patient
influenza
demonstr
use
peramivir
mg
twice
daili
mg
daili
day
reduc
viral
shed
produc
clinic
improv
author
report
crossresist
oseltamivir
peramivir
immunocompromis
patient
infect
influenza
viru
contain
variant
therefor
patient
infect
influenza
viru
suspect
document
substitut
receiv
peramivir
diarrhea
common
report
advers
effect
peramivir
seriou
reaction
associ
central
nervou
system
includ
delirium
abnorm
behavior
lead
injuri
patient
influenza
receiv
oseltamivir
peramivir
primarili
report
among
children
neurolog
event
often
began
abruptli
resolv
rapidli
contribut
treatment
neuraminidas
inhibitor
event
yet
establish
advers
event
may
relat
influenza
infect
rather
treatment
author
frequent
report
neuropsychiatr
symptom
children
influenza
infect
symptom
alway
associ
treatment
neuraminidas
inhibitor
ansun
biopharma
san
diego
ca
usa
recombin
fusion
protein
sialidas
deriv
actinomycos
viscosu
cleav
sialic
acid
receptor
host
cell
figur
protein
bind
cell
effici
remov
cellsurfac
sialic
acid
residu
respiratori
epithelium
inhibit
viral
infect
consid
target
host
cell
rather
viru
less
like
virustarget
drug
induc
treatment
resist
da
administ
via
inhal
exhibit
preclin
activ
numer
strain
influenza
b
parainfluenza
virus
piv
phase
ii
doubleblind
placebocontrol
clinic
trial
assess
influenza
viral
load
patient
safeti
otherwis
healthi
influenzainfect
particip
inhal
dosag
mg
per
day
reduc
viral
load
viral
shed
multipledos
group
patient
take
placebo
measur
use
quantit
polymeras
chain
reaction
p
howev
differ
allevi
flulik
symptom
placebo
treatment
arm
overal
well
toler
day
administ
via
daili
inhal
day
except
thrombocytopenia
liver
test
abnorm
instanc
favipiravir
toyama
chemic
tokyo
japan
investig
antivir
drug
function
nucleotid
analog
inhibitor
viral
rna
polymeras
influenza
favipiravir
activ
broad
rang
influenza
b
c
virus
includ
highli
pathogen
avian
novel
avian
virus
well
influenza
virus
resist
treatment
nai
inhibitor
studi
preclin
cellular
mice
model
demonstr
synergi
favipiravir
oseltamivir
drug
current
test
phase
iii
clinic
trial
usa
europ
latin
america
laninamivir
biota
pharmaceut
alpharetta
ga
usa
longact
nai
administ
via
drypowd
inhal
phase
iii
random
control
trial
demonstr
superior
singl
inhal
dose
laninamivir
octano
cours
oral
oseltamivir
adult
season
influenza
drug
potenti
effect
oseltamivirresist
virus
current
avail
japan
laninamivir
demonstr
effect
reduc
transmiss
influenza
infect
patient
household
contact
random
trial
household
contact
patient
influenza
infect
randomli
assign
receiv
singl
dose
laninamivir
dose
laninamivir
given
daili
day
placebo
famili
member
laninamivir
group
less
like
develop
clinic
influenza
compar
placebo
group
daiichi
sankyo
compani
ltd
japan
plan
studi
drug
prevent
influenza
singl
inhal
dose
adult
children
janssen
pharma
titusvil
usa
nonnucleosid
inhibitor
target
influenza
rna
polymeras
protein
inhibit
product
viral
mrna
prevent
cell
death
demonstr
activ
influenza
strain
test
vitro
human
studi
demonstr
signific
decreas
viru
shed
administ
load
dose
mg
first
day
follow
mg
daili
day
phase
iib
trial
evalu
dose
frequenc
drug
healthi
patient
uncompl
influenza
infect
current
way
nitazoxanid
romark
laboratori
florida
usa
antiparasit
agent
appear
inhibit
matur
influenza
viru
ha
phase
iibiii
trial
treatment
nitazoxanid
mg
twice
daili
day
associ
reduct
symptom
durat
viral
titer
among
patient
acut
uncompl
influenza
infect
nitazoxanid
also
shown
synergist
effect
vitro
nai
current
phase
iii
trial
investig
efficaci
synerg
complet
result
await
astrazeneca
gaithersburg
maryland
usa
monoclon
antibodi
target
highli
conserv
epitop
ha
stalk
influenza
viru
current
evalu
phase
ibiia
clinic
trial
safeti
efficaci
singl
intraven
dose
combin
oseltamivir
monotherapi
adult
patient
confirm
acut
uncompl
influenza
infect
visterra
inc
cambridg
usa
neutral
human
antiha
antibodi
bind
conserv
region
ha
stalk
influenza
viru
mice
result
protect
influenza
infect
administ
prophylact
coinfect
bacteri
pathogen
influenza
infect
may
lead
signific
morbid
mortal
bacteri
coinfect
associ
increas
diseas
sever
hospit
admiss
even
mortal
streptococcu
pneumonia
staphylococcu
aureu
common
pathogen
set
follow
haemophilu
influenza
group
streptococci
recent
metaanalysi
klein
et
al
note
older
age
higher
apach
ii
acut
physiolog
chronic
health
evalu
ii
score
diabet
mellitu
sepsi
risk
factor
predispos
coinfect
american
colleg
immun
practic
acip
recommend
simultan
antivir
antibiot
treatment
sever
ill
patient
influenza
infect
consist
acip
guidelin
infecti
diseas
societi
america
idsa
guidelin
recommend
appropri
use
diagnost
test
guidanc
target
antibacteri
therapi
hospit
patient
recommend
antibacteri
therapi
includ
cefotaxim
ceftriaxon
respiratori
fluoroquinolon
treatment
vancomycin
linezolid
agent
direct
methicillinresist
staphylococcu
aureu
mrsa
recommend
patient
confirm
compat
clinic
present
mrsa
infect
ie
shock
necrot
pneumonia
respiratori
syncyti
viru
rsv
envelop
singlestrand
rna
viru
famili
paramyxovirida
frequent
caus
season
upper
respiratori
viral
infect
infant
young
children
symptomat
rsv
reinfect
immunocompet
adult
often
consist
urti
last
day
immunocompromis
patient
hsct
solidorgan
transplant
recipi
rsv
infect
may
progress
sever
lifethreaten
lrti
investig
univers
texa
md
anderson
cancer
center
develop
immunodefici
score
index
rsv
account
major
risk
factor
identifi
hsct
recipi
high
risk
progress
rsv
infect
lrti
rsvassoci
mortal
age
neutropenia
lymphocytopenia
graftversushost
diseas
use
myeloabl
condit
regimen
use
corticosteroid
recent
hsct
preengraft
main
risk
factor
weigh
index
categor
patient
prognost
risk
group
low
moder
high
risk
author
report
statist
signific
trend
higher
incid
lrtiand
rsv
infectionassoci
mortal
risk
increas
low
moder
high
p
patient
highrisk
group
demonstr
greatest
benefit
ribavirinbas
therapi
urti
stage
highest
risk
progress
lrti
death
absenc
antivir
therapi
suggest
use
immunodefici
score
index
rsv
identifi
highrisk
patient
would
benefit
treatment
aerosol
ribavirin
seen
hsct
recipi
research
note
associ
low
lymphocyt
count
mean
cellsmm
rsv
infect
progress
lrti
solidorgan
transplant
recipi
lung
transplant
recipi
highest
risk
advers
outcom
ribavirin
nucleosid
analog
resembl
guanosin
monophosph
ribavirin
inhibit
dehydrogenas
enzym
essenti
synthesi
guanosin
triphosph
reduc
cellular
deposit
guanidin
necessari
viral
growth
inhibit
initi
elong
rna
fragment
result
inhibit
viral
protein
synthesi
figur
aerosol
ribavirin
fdaapprov
treatment
sever
rsvlrti
hospit
infant
young
children
underli
compromis
condit
prematur
cardiopulmonari
diseas
immunosuppress
rsv
infect
markedli
increas
morbid
mortal
rate
hsct
recipi
ribavirinbas
antivir
therapi
recommend
european
guidelin
leukemia
patient
hsct
recipi
high
risk
complic
systemat
review
literatur
shah
et
al
base
mainli
retrospect
studi
form
ribavirinbas
therapi
alon
combin
immunomodul
prevent
urti
progress
lrti
improv
mortal
rate
compar
therapi
adult
hsct
recipi
whether
benefit
aerosol
ribavirin
versu
oral
form
justifi
use
immunocompromis
patient
remain
subject
controversi
especi
given
recent
drastic
increas
cost
aerosol
form
research
systemat
review
use
oral
ribavirin
treat
variou
respiratori
viral
infect
includ
rsv
infect
author
conclud
mortal
rate
highli
variabl
often
depend
underli
sever
ill
rather
effect
oral
ribavirin
howev
random
control
studi
avail
evalu
khanna
et
al
report
oral
ribavirin
good
safeti
profil
rsvinfect
patient
upper
lower
respiratori
tract
infect
could
draw
strong
conclus
regard
efficaci
dose
recommend
european
confer
infect
leukaemia
guidelin
includ
load
dose
mg
follow
mg
everi
h
first
day
mg
everi
h
second
day
escal
daili
maximum
mgkgday
iv
formul
ribavirin
benefici
case
rsv
infect
trial
need
variou
therapi
intraven
immunoglobulin
ivig
rsv
hyperimmunoglobulin
palivizumab
monoclon
rsv
igg
use
treatment
prevent
rsv
infect
immunocompromis
patient
mix
result
earli
studi
demonstr
ribavirin
combin
rsv
ivig
respigam
medimmun
gaithersburg
md
usa
hyperimmun
globulin
prepar
high
concentr
rsvneutral
antibodi
offer
mortal
advantag
ribavirin
alon
rsvinfect
pediatr
hsct
recipi
lrti
howev
product
rsv
ivig
sinc
discontinu
introduct
altern
palivizumab
engin
antirsv
monoclon
antibodi
palivizumab
current
approv
prophylaxi
rsv
infect
select
group
highrisk
infant
bronchopulmonari
dysplasia
infant
histori
prematur
birth
gestat
age
children
younger
month
hemodynam
signific
congenit
heart
diseas
rsv
infect
season
american
academi
pediatr
recommend
palivizumab
dose
bodi
weight
administ
monthli
throughout
rsv
infect
season
first
dose
administ
prior
commenc
season
maximum
dose
per
season
kassi
et
al
demonstr
util
palivizumab
prophylaxi
hsct
unit
follow
rsv
infect
outbreak
palivizumab
use
prevent
rsv
infect
rsvneg
patient
consid
high
risk
complic
rsv
infect
combin
strict
infectioncontrol
measur
contrast
palivizumab
fail
demonstr
impact
progress
lrti
mortal
case
seri
allogen
hsct
recipi
infect
rsv
given
question
efficaci
high
cost
palivizumab
mainli
adult
patient
routin
use
encourag
adult
immunocompromis
popul
adult
hsct
recipi
rsv
pneumonia
uncontrol
studi
suggest
use
combin
therapi
ribavirin
ivig
improv
surviv
addit
studi
rsvinfect
lung
transplant
recipi
demonstr
combin
treatment
ribavirin
nebul
iv
ivig
andor
corticosteroid
reduc
mortal
rate
length
mechan
ventil
incid
bronchiol
obliteran
although
combin
use
ribavirin
ivig
support
random
trial
expens
treatment
reserv
select
patient
rsvrelat
lrti
sever
immun
defici
alnylam
pharmaceut
cambridg
usa
smallinterf
rna
sirna
inhibit
rsv
replic
interrupt
synthesi
viral
nucleocapsid
protein
treatment
compound
demonstr
promis
result
phase
ii
clinic
trial
rna
interfer
natur
process
sirna
induc
sequencespecif
degrad
mrna
thu
reduc
express
correspond
protein
random
doubleblind
placebocontrol
trial
research
administ
prophylact
nasal
spray
experiment
inocul
healthi
adult
wildtyp
rsv
observ
reduct
number
infect
phase
iia
random
doubleblind
placebocontrol
trial
adult
lung
transplant
recipi
confirm
rsv
urti
use
aerosol
mgkg
daili
day
significantli
reduc
mean
cumul
daili
symptom
score
p
incid
progress
bronchiol
obliteran
syndrom
day
patient
given
placebo
vs
p
also
recent
phase
iib
trial
lung
transplant
recipi
demonstr
trend
decreas
new
progress
bronchiol
obliteran
bo
incid
vs
p
day
treatment
effect
enhanc
initi
use
fewer
day
symptom
onset
whether
develop
compound
would
pursu
remain
unknown
present
time
microdos
therapeutx
monmouth
junction
nj
usa
gilead
scienc
foster
citi
ca
usa
gilead
scienc
foster
citi
ca
usa
antivir
fusion
inhibitor
oral
shown
safeti
toler
healthi
adult
current
two
phase
iib
trial
underway
evalu
antivir
effect
pharmacokinet
safeti
toler
hsct
recipi
either
rsv
uri
lrti
deliv
dryinhal
powder
evalu
phase
ii
trial
assess
safeti
toler
healthi
adult
alio
south
san
francisco
ca
usa
nucleosid
inhibitor
lprotein
demonstr
efficaci
human
challeng
studi
lprotein
rnadepend
rna
polymeras
rsv
inhibit
impact
futur
viral
replic
random
doubleblind
placebocontrol
phase
ii
challeng
studi
conduct
healthi
adult
volunt
infect
intranas
rsv
well
toler
demonstr
signific
reduct
rsv
viral
load
p
improv
symptom
score
p
compar
placebo
polyclon
hightit
rsv
immunoglobulin
adma
biolog
inc
hackensack
nj
usa
test
patient
immunocompromis
prevent
progress
urti
lrti
preliminari
result
pend
motavizumab
newli
develop
monoclon
antibodi
target
highli
conserv
antigen
site
fusion
glycoprotein
rsv
antivir
effect
hospit
children
superior
palivizumab
season
rsv
prophylaxi
preterm
infant
chronic
lung
diseas
prematur
atrisk
rsv
relat
lrti
hospit
death
fda
antivir
drug
advisori
committe
declin
request
licensur
motavizumab
concern
rais
includ
lack
addit
benefit
motavizumab
palivizumab
addit
risk
cutan
hypersensit
reaction
parainfluenza
viru
piv
singlestrand
envelop
rna
paramyxoviru
compris
antigen
share
serotyp
although
clinic
piv
infect
caus
type
gener
popul
clinic
piv
infect
caus
follow
although
piv
infect
often
occur
year
round
peak
season
activ
reportedli
occur
late
septemb
decemb
spring
summer
month
piv
commonli
affect
upper
respiratori
tract
incub
period
day
commonli
associ
urti
children
immunocompromis
patient
author
describ
progress
lrti
hsct
recipi
pivinfect
patient
hematolog
malign
risk
factor
progress
pivurti
pivlrti
includ
lymphocytopenia
neutropenia
onset
infect
use
corticosteroid
pivurti
respiratori
coinfect
risk
factor
pivrel
mortal
includ
lymphocytopenia
young
age
year
refractori
relaps
underli
hematolog
malign
acut
physiolog
chronic
health
evalu
ii
score
greater
respiratori
coinfect
steroid
use
infect
onset
antivir
agent
licens
treat
piv
manag
limit
support
care
instanc
physician
use
oral
aerosol
ribavirin
without
ivig
treatment
piv
lrti
immunocompromis
patient
variou
outcom
new
antivir
agent
vaccin
pipelin
may
chang
paradigm
piv
infect
manag
particularli
immunocompromis
patient
although
describ
clinic
provid
use
oral
aerosol
ribavirin
treat
piv
avail
data
use
infect
remain
controversi
two
recent
systemat
review
hsct
recipi
hematolog
malign
patient
demonstr
ribavirin
significantli
effect
prevent
progress
urti
lrti
pivassoci
mortal
support
care
alon
also
lung
transplant
recipi
piv
infect
use
oral
ribavirin
day
mgkgday
divid
dose
dose
length
associ
benefit
includ
lower
rate
bronchiol
obliteran
syndrom
within
month
develop
infect
nonribavirin
group
vs
p
given
lack
clear
evid
posit
outcom
pivinfect
patient
well
absenc
control
studi
justifi
recommend
use
ribavirin
treatment
piv
immunocompromis
patient
made
describ
novel
sialidas
fusion
protein
activ
piv
vivo
vitro
effect
cleav
sialic
acid
respiratori
epitheli
cell
prevent
piv
entri
cell
figur
da
administ
compassionateus
basi
sever
piv
infect
immunocompromis
patient
appar
clinic
benefit
antivir
effect
case
seri
pediatr
hsct
recipi
piv
detect
respiratori
specimen
upper
respiratori
tract
lower
respiratori
tract
receiv
inhal
day
oxygen
requir
respiratori
rate
improv
patient
viral
load
decreas
within
week
therapi
initi
similar
case
seri
hsct
recipi
receiv
daili
treat
piv
infect
lrti
urti
patient
complet
clinic
respons
patient
partial
respons
therapi
patient
virolog
spirometr
data
reduct
piv
viral
load
nasopharyng
secret
improv
forc
expiratori
volum
end
treatment
ongo
phase
ii
doubleblind
placebocontrol
trial
investig
examin
effect
immunocompromis
patient
pivrel
pneumonia
recent
report
describ
use
hsct
recipi
respons
therapi
partial
respons
also
greater
reduct
piv
viral
load
biocryst
pharmaceut
inc
birmingham
al
usa
new
antivir
hemagglutinin
neuraminidas
inhibitor
evalu
mous
model
infect
viru
similar
piv
recombin
sendai
viru
demonstr
antivir
activ
markedli
reduc
pulmonari
viral
titer
mortal
rate
rat
given
intranas
within
h
develop
infect
human
studi
two
inhibitor
yet
undertaken
human
rhinovirus
hrv
positivesens
singlestrand
rna
virus
icosahedr
symmetri
character
three
genet
distinct
group
design
b
c
within
genu
enteroviru
famili
picornavirida
viral
capsid
encas
rna
genom
made
four
protein
remain
nonstructur
protein
involv
viral
genom
replic
assembl
hrv
infect
respons
one
half
coldlik
ill
cost
billion
dollar
annual
medic
visit
miss
day
work
usa
peak
incid
occur
earli
fall
smaller
peak
spring
peak
incid
associ
urti
otiti
media
sinus
recent
studi
patient
go
emerg
room
influenzalik
ill
also
hematolog
malign
demonstr
patient
present
hrv
infect
research
found
sever
hrv
infect
patient
similar
influenza
pandem
nearli
patient
hrvassoci
respiratori
symptom
admit
hospit
lrti
need
intens
care
unit
admiss
studi
includ
hsct
recipi
replic
result
marker
increas
immunosuppress
ill
sever
patient
hrv
infect
includ
neutropenia
absolut
neutrophil
count
hypoalbuminemia
serum
albumin
level
mgdl
infect
respiratori
copathogen
associ
progress
hrvrelat
pneumonia
contrast
parodi
et
al
describ
much
lower
rate
progress
lrti
similar
patient
popul
use
differ
case
definit
hrv
infect
may
explain
dispar
preval
lrti
two
report
chronic
hrv
infect
occur
lung
transplant
patient
furthermor
studi
adult
lung
transplant
recipi
bronchoalveolar
fluid
specimen
obtain
symptomat
patient
period
posit
hrv
current
treatment
hrv
infect
consist
support
care
antivir
medic
hrv
investig
viral
capsid
initi
viral
protein
target
develop
drug
inhibit
viral
replic
drug
work
bind
hydrophob
pocket
viral
capsid
result
conform
chang
increas
stabil
virion
interf
abil
interact
cellular
receptor
vapendavir
aviragen
therapeut
alpharetta
ga
usa
oral
agent
bind
hrv
capsid
protein
prevent
releas
viral
rna
target
cell
vapendavir
exhibit
antivir
activ
hrva
hrvb
serotyp
howev
activ
hrvc
yet
known
phase
ii
random
doubleblind
placebocontrol
studi
asthmat
adult
hrv
urti
show
lower
sever
score
cold
symptom
greater
mean
reduct
asthma
score
higher
even
peak
expiratori
flow
given
vapendavir
placebo
pleconaril
viropharma
exton
pa
usa
first
develop
capsidbind
antihrv
agent
two
phase
iii
multicent
studi
usa
canada
random
healthi
subject
selfdiagnos
cold
group
receiv
pleconaril
mg
oral
twice
daili
placebo
day
primaryefficaci
popul
consist
subject
hrv
rna
detect
nasal
secret
pleconariltr
subject
experienc
reduct
mean
durat
ill
compar
placebo
group
day
versu
day
p
anoth
studi
research
found
associ
hrv
suscept
pleconaril
clinic
outcom
fda
declin
licens
pleconaril
owe
concern
develop
resist
viru
strain
addit
interact
among
cytochrom
hormon
contracept
antiretrovir
therapi
human
immunodefici
viral
infect
may
reduc
effect
pleconaril
rupintrivir
agouron
pharmaceut
inc
san
diego
ca
usa
vitro
proteas
inhibitor
act
mani
hrv
enterovirus
rupintrivir
reduc
viral
load
respiratori
symptom
healthi
volunt
experiment
induc
rhinoviru
cold
well
toler
particip
howev
trial
patient
natur
infect
rupintrivir
fail
reduc
viral
load
symptom
sever
inhal
interferonbeta
synairgen
plc
southampton
england
test
phase
ii
placebo
control
random
trial
adult
asthmat
receiv
inhal
corticosteroid
histori
deterior
cold
associ
signific
improv
asthma
symptom
fewer
moder
exacerb
improv
morn
peak
expiratori
flow
rate
reduc
use
relief
bronchodil
human
metapneumoviru
hmpv
envelop
negativesens
singlestrand
rna
viru
first
human
member
metapneumoviru
genu
pneumovirina
subfamili
within
paramyxovirida
famili
first
identifi
netherland
serolog
studi
antibodi
hmpv
indic
viru
circul
human
least
year
phylogenet
analysi
identifi
two
genotyp
hmpv
hmpv
hmpv
b
hmpv
use
fusion
mechan
penetr
target
cell
fusion
process
consist
insert
hydrophob
fusion
peptid
target
cell
membran
refold
f
protein
step
requir
interact
two
specif
domain
heptad
repeat
b
investig
studi
process
develop
potenti
antivir
treatment
hmpv
caus
respiratori
infect
season
distribut
compar
influenza
rsv
infect
although
immunocompromis
patient
acquir
hmpv
infect
frequenc
immunocompet
individu
higher
risk
sever
infect
higher
risk
like
attribut
poor
viral
clearanc
recent
systemat
review
hsct
recipi
hematolog
malign
patient
estim
incid
progress
hmpvurti
lrti
associ
mortal
rate
factor
associ
progress
hsct
recipi
includ
earli
onset
infect
transplant
steroid
use
low
lymphocyt
count
date
treatment
hmpv
infect
mainli
support
research
investig
sever
treatment
regimen
standard
immunoglobulin
prepar
inhibit
replic
hmpv
vitro
approach
use
select
immunoglobulin
fusion
inhibitor
demonstr
antivir
activ
vitro
anim
studi
administr
oral
aerosol
ribavirin
without
polyclon
ivig
advoc
treatment
sever
hmpv
infect
current
use
center
highrisk
patient
although
data
still
anecdot
fusion
inhibitor
target
initi
step
viral
fusion
penetr
human
cell
fusion
inhibitor
sequenc
similar
hra
hrb
domain
viral
fusion
protein
demonstr
import
role
viral
inhibit
balbc
mice
inocul
lethal
intranas
hmpv
challeng
complet
protect
clinic
symptom
mortal
simultan
receiv
peptid
peptid
also
demonstr
effect
viral
inhibitor
research
develop
mab
medimmun
gaithersburg
md
usa
target
hmpv
fusion
protein
appear
effect
neutral
hmpv
golden
syrian
hamster
model
reduc
pulmonari
viral
titer
therebi
limit
sever
acut
manifest
bronchial
hyperreact
human
monoclon
antibodi
fragment
human
fab
biolog
activ
fusion
protein
hmpv
demonstr
prophylact
therapeut
potenti
sever
hmpv
infect
test
cotton
rat
human
coronaviru
hcov
singlestrand
envelop
rna
viru
belong
famili
coronavirida
temper
climat
hcov
infect
transmit
primarili
winter
wellrecogn
caus
urti
respiratori
viral
season
usual
mild
immunocompet
host
hcov
infect
immunocompromis
popul
may
progress
lrti
emerg
hcov
sever
acut
respiratori
syndromeassoci
hcov
recent
identifi
middl
east
respiratori
syndrom
prompt
impetu
develop
therapeut
infect
current
antivir
agent
lack
treatment
remain
palli
discoveri
vitro
evalu
hcov
therapi
ongo
includ
investig
entri
inhibitor
human
monoclon
antibodi
proteosom
inhibitor
respiratori
viral
infect
continu
major
clinic
problem
immunocompromis
patient
high
clinic
suspicion
use
rapid
diagnost
test
remain
crucial
earli
treatment
associ
improv
outcom
reduc
transmiss
sever
advanc
prevent
treatment
influenza
infect
occur
recent
decad
inadequ
efficaci
influenza
vaccin
well
emerg
antivir
resist
appear
occur
commonli
immunocompromis
patient
healthi
host
underlin
difficulti
manag
respiratori
infect
immunocompromis
individu
rsv
piv
infect
continu
associ
high
morbid
mortal
advanc
prevent
therapi
respiratori
viral
infect
need
impact
rhinoviru
coronaviru
metapneumoviru
infect
patient
compromis
immun
system
becom
evid
new
wide
avail
molecular
test
improv
recognit
viral
infect
past
decad
import
diagnost
advanc
specif
use
rapid
molecular
test
help
close
gap
clinic
scenario
pathogen
identif
enhanc
earli
diagnosi
viral
infect
understand
role
prolong
shed
viral
load
respiratori
viral
infect
complic
clinician
immunocompromis
patient
futur
studi
identifi
valid
score
system
ascertain
patient
highest
risk
complic
respiratori
viral
infect
includ
lrti
utmost
import
also
identif
longterm
complic
respiratori
viral
infect
immunocompromis
patient
devis
intervent
prevent
utmost
valu
last
advanc
novel
antivir
therapeut
highresist
threshold
effect
immun
prevent
infect
immunocompromis
patient
need
curtail
impact
respiratori
virus
immunocompromis
patient
focu
prevent
exposur
progress
wors
outcom
multipl
intervent
modal
studi
stimul
innat
immun
system
respons
immun
new
antivir
therapi
avert
infect
progress
lower
tract
respiratori
infect
one
main
challeng
immunocompromis
patient
abil
clear
infect
subsequ
complic
associ
worsen
infect
prolong
shed
risk
resist
coinfect
treatment
target
viral
replic
also
immun
respons
infect
may
offer
better
outcom
last
understand
role
microbiom
virom
implic
transmiss
well
develop
infect
key
develop
new
strategi
respiratori
virus
frequent
caus
respiratori
infect
immunocompromis
patient
associ
higher
rate
progress
pneumonia
respiratori
failur
death
high
preval
inhibitor
resist
detect
influenza
viru
strain
preclud
use
prophylaxi
empir
treatment
season
influenza
neuraminidas
inhibitor
first
line
agent
treatment
influenza
treatment
like
provid
benefit
initi
within
first
h
ill
zanamivir
current
therapi
choic
treatment
oseltamivirresist
influenza
infect
immunodefici
score
index
rsv
account
number
risk
factor
use
identifi
hsct
recipi
high
risk
progress
rsv
lrti
rsv
associ
mortal
ribavirinbas
therapi
alon
combin
immunomodul
effect
prevent
progress
urti
lrti
may
improv
mortal
highli
immunosuppress
adult
hsct
recipi
safeti
efficaci
immunocompromis
patient
piv
pneumonia
current
studi
ongo
phase
doubleblind
placebocontrol
trial
vapendavir
bind
hrv
capsid
protein
prevent
releas
viral
rna
target
cell
demonstr
favor
result
asthmat
adult
hrv
urti
antivir
agent
hmpv
hcov
still
studi
vitro
anim
model
paper
fund
ej
arizaheredia
receiv
research
grant
oxford
immunotec
rf
chemali
receiv
research
grant
gilead
gsk
ansun
pharmaceut
honoraria
adma
biolog
gilead
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
